Entering text into the input field will update the search result below
Join now
Search for Symbols, analysts, keywords
Log in
ADAP
Adaptimmune Therapeutics plc
Latest News
Follow
$0.70
-0.06 (-7.89%)
3:21 PM 10/04/23
NASDAQ |
$USD |
Realtime
Summary
Ratings
Financials
Earnings
Dividends
Valuation
Growth
Profitability
Momentum
Peers
Options
Charting
All
Analysis
Comments
News
Transcripts
SEC Filings
Press Releases
Related Analysis
News
Show Full Stories
Show Full Stories
This feature available only for pro users
Type:
All Types
Date Range:
Select Date
Adaptimmune GAAP EPS of -$0.02 beats by $0.19, revenue of $5.13M misses by $1.54M
Adaptimmune Q2 2023 Earnings Preview
Adaptimmune completes merger with fellow immunology company TCR2
Adaptimmune GAAP EPS of $0.00 beats by $0.14, revenue of $47.6M
Adaptimmune Q1 2023 Earnings Preview
TCR2 Therapeutics GAAP EPS of -$1.03 misses by $0.34
Adaptimmune, TCR2 Therapeutics set May 30 for shareholder votes on deal
Adaptimmune to regain rights to cancer drug programs from GSK
TCR2 Therapeutics GAAP EPS of -$1.56 misses by $0.74
Cara, Iovance, and Karyopharm among biotechs with no exposure to SVB (updated)
Adaptimmune sheds nearly 26% after strategic combination with TCR² Therapeutics; tops Q4 consensus
Adaptimmune GAAP EPS of -$0.03 beats by $0.20, revenue of $11.03M beats by $5.95M
TCR² Therapeutics stock rise 41% after merger deal with Adaptimmune
Adaptimmune Q4 2022 Earnings Preview
Adaptimmune stock soars ~15% as Guggenheim upgrades rating to Buy
Adaptimmune Therapeutics upgraded at Mizuho on clarity for afami-cel
TCR2 Therapeutics GAAP EPS of -$0.79 beats by $0.06
Adaptimmune GAAP EPS of -$0.04 beats by $0.22, revenue of $7M beats by $2.03M
Adaptimmune stock rises as drug shows promise across cancer types in phase 1 trial
Adaptimmune Q3 2022 Earnings Preview
GSK to transfer back cancer drug programs to Adaptimmune
TCR2 Therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trial
Adaptimmune updates early-stage data for solid tumor candidate
WKHS, BTU and LYG are among pre market gainers
TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Adaptimmune Non-GAAP EPS of -$0.05 beats by $0.24, revenue of $5.54M misses by $3.16M
Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Adaptimmune Q2 2022 Earnings Preview
TCR² Therapeutics appoints Eric Sullivan as CFO
Catalyst watch: Twitter drama, high-profile Block and Caterpillar events, Jerome Powell talks
TCR2 Therapeutics GAAP EPS of -$0.76 misses by $0.01
Adaptimmune GAAP EPS of -$0.05 beats by $0.19, revenue of $3.6M misses by $1.4M
Adaptimmune in two-day rally thanks to Regeneron/Checkmate deal; shares up 15%
Adaptimmune Therapeutics drops 5% on $400 mixed shelf offering
Adaptimmune files for $400M mixed shelf offering; shares down 5% after hours
TCR2 Therapeutics GAAP EPS of -$0.72 beats by $0.04
Adaptimmune GAAP EPS of -$0.04, revenue of $1.4M
Arvinas, Arrowhead win Buy ratings as Goldman Sachs starts coverage on platform biotechs
Adaptimmune says mid-stage trial for afami-cel in soft tissue cancer will meet main goal
TCR2 Therapeutics EPS misses by $0.02
1
2
3
4
5
Next
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.